CPN News Alert Calpine Corp (CPN) 20.52 12/12/2014 23:08:54

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Calpine Corp (CPN) 20.52 $CPN

Upgrade Alert for Calpine (CPN)
Comtex SmarTrend(R) - Mon Dec 08, 7:03AM CST
Calpine (NYSE:CPN) was upgraded from Neutral to Outperform at Macquarie today. The stock closed yesterday at $21.90 on volume of 5.2 million shares, above average daily volume of 4.2 million. Calpine Corporation acquires, develops, owns, and operates power generation facilities, as well as sells electricity in the United States. The Company also provides thermal energy for industrial customers.
CPN: 20.52 (-0.65)

SmarTrend Watching for Potential Rebound in Shares of Calpine After 2.76% Loss
Comtex SmarTrend(R) - Wed Dec 03, 4:10PM CST
Calpine (NYSE:CPN) traded in a range yesterday that spanned from a low of $21.39 to a high of $22.40. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $22.33 on volume of 10.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CPN: 20.52 (-0.65)

Watch for Calpine to Potentially Rebound After Falling 2.76% Yesterday
Comtex SmarTrend(R) - Wed Dec 03, 4:10PM CST
Calpine (NYSE:CPN) traded in a range yesterday that spanned from a low of $21.39 to a high of $22.40. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $22.33 on volume of 10.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CPN: 20.52 (-0.65)

Calpine Falls 1.68% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Nov 25, 4:32PM CST
Calpine (NYSE:CPN) traded in a range yesterday that spanned from a low of $22.82 to a high of $23.34. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $23.07 on volume of 5.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CPN: 20.52 (-0.65)

Calpine Earnings Hindsight: Down 3.0% in Last 18 Days (CPN)
Comtex SmarTrend(R) - Mon Nov 24, 7:56AM CST
When Calpine (NYSE:CPN) reported earnings 18 days ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $0.62 on sales of $1.9 billion. Calpine actually reported earnings of $0.76 per share on sales of $2.2 billion, beating EPS estimates by $0.14 and beating revenue estimates by $305.4 million. Since the company's report, shares of Calpine have fallen from $24.05 to $23.33, representing a loss of 3.0% in the past 18 days.
CPN: 20.52 (-0.65)

Calpine Earnings Review: 11 Days after Announcement Shares Down 1.9% (CPN)
Comtex SmarTrend(R) - Mon Nov 17, 11:05AM CST
11 days ago, on November 6th, 2014, Calpine (NYSE:CPN) reported its earnings. Analysts, on average, expected earnings of $0.62 per share on sales of $1.9 billion. The company actually reported EPS of $0.76 on sales of $2.2 billion, beating EPS estimates by $0.14 and beating revenue estimates by $305.4 million. Since the company's report, shares of Calpine have fallen from $24.05 to $23.60, representing a loss of 1.9% in the past 11 days.
CPN: 20.52 (-0.65)

Momentum Indicators for Utilities Sector Equities - AES Corp., NRG Energy, Calpine, Dynegy, and Atlantic Power
PR Newswire - Mon Nov 17, 8:30AM CST
Investor-Edge has initiated coverage on the following equities: AES Corporation (NYSE: AES), NRG Energy Inc. (NYSE: NRG), Calpine Corporation (NYSE: CPN), Dynegy Inc. (NYSE: DYN), and Atlantic Power Corporation (NYSE: AT). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 14, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,634.74, down 0.10% and the NASDAQ Composite closed at 4,688.54, up 0.18%. The S&P 500 finished the session 0.02% higher at 2,039.82. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Utilities Sector Index ended the day at 227.44, down 0.38%, whereas the index has advanced 7.21% in the previous three months. Register for your complimentary reports on these five stocks at:
AT: 2.35 (+0.01), CPN: 20.52 (-0.65), AES: 13.29 (+0.08), DYN: 28.58 (-0.57), NRG: 26.66 (-0.26)

Calpine Insiders Opting Into Their Shares
InsiderInsights - at Seeking Alpha - Thu Nov 13, 6:57AM CST

CPN: 20.52 (-0.65)

Chicago Bridge lands two new contracts
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:26AM CST

CBI: 39.14 (-1.17), CPN: 20.52 (-0.65)

CB&I Announces Award for 760 Megawatt Combined-Cycle Gas Turbine Power Station
PR Newswire - Tue Nov 11, 7:00AM CST
CB&I (NYSE:CBI) today announced it has been awarded a contract by Calpine Mid-Merit, LLC, an affiliate of Calpine Corp., for the initial development phase of a combined-cycle gas turbine power station in Peach Bottom Township, Pennsylvania. The 760 megawatt unit will be built adjacent to the existing York Energy Center.
CBI: 39.14 (-1.17), CPN: 20.52 (-0.65)

Calpine acquires USD530m Fore River Energy Center in Massachusetts, southeast of Boston
M2 - Mon Nov 10, 6:06AM CST
Electricity company Calpine (NYSE:CPN) disclosed on Friday the completion of the acquisition of a natural gas-fired, 809 megawatts, combined-cycle power plant (the Fore River Energy Center) in North Weymouth, Massachusetts, southeast of Boston.
CPN: 20.52 (-0.65)

Calpine Completes Purchase of Fore River Energy Center in New England for $530 Million
Business Wire - Fri Nov 07, 11:09AM CST
Calpine Corporation (NYSE:CPN) today completed the acquisition of a natural gas-fired, combined-cycle power plant located in North Weymouth, Massachusetts, 12 miles southeast of Boston. Calpine purchased the plant, which has a nameplate generating capacity of 809 megawatts, from Exelon Corporation for $530 million plus adjustments, or approximately $655 per kilowatt. The transaction was funded with cash on hand, which Calpine expects to replenish through a financing later this year.
CPN: 20.52 (-0.65), EXC: 35.92 (-0.35)

Calpine's (CPN) CEO John Hill on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:20PM CST

CPN: 20.52 (-0.65)

Calpine (CPN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:55AM CST

CPN: 20.52 (-0.65)

Calpine beats Street 3Q forecasts
Automated Insights - Thu Nov 06, 5:24AM CST
HOUSTON (AP) _ Calpine Corp. (CPN) on Thursday reported earnings of $614 million in its third quarter.
CPN: 20.52 (-0.65)

Calpine beats by $0.97, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 5:05AM CST

CPN: 20.52 (-0.65)

Calpine Reports Third Quarter Results, Narrows 2014 Guidance and Provides 2015 Guidance
Business Wire - Thu Nov 06, 5:01AM CST
Calpine Corporation (NYSE: CPN)
CPN: 20.52 (-0.65)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 75

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 324

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 90

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 345

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Forecast and Expectations for Anika Therapeutics

Updated Category News Views 118

Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...

Continue Reading
QYOU Media's Strategic Shift Towards a Creator-Focused Future

Updated Category News Views 202

QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...

Continue Reading
Understanding Recent Disclosures from Octopus Investments

Updated Category News Views 106

Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....

Continue Reading
LiTime's Innovative Battery Solutions Shine in European RV Market

Updated Category News Views 297

LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...

Continue Reading
Oncolytics Biotech Appoints Jared Kelly as New CEO to Lead Growth

Updated Category News Views 263

Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...

Continue Reading